There is a growing body of clinical and preclinical evidence that therapeutic hepcidin plays an important role in a wide range of hematologic diseases. This includes conditions such as polycythemia vera (PV), hereditary hemochromatosis, myelodysplastic syndromes (MDS) and β-thalassemia. Across these disease states, patients develop dangerously high levels of iron, resulting in complications that impact survival and daily life. While a number of injectable options are currently in development to increase or mimic hepcidin function, we believe there is a significant need for an effective oral treatment to provide optimal control of iron levels, as these conditions require chronic therapy.